Don't miss any news, subscribe to our press releases.
In November 2025, Sprint Bioscience announced the sale of the TREX1 cancer program. The deal includes an upfront payment of USD 14 million and potential milestone payments linked to clinical, regulatory and commercial progress, which could total up to USD 400 million.
Read more on the press releases page.